Willem Jacobus De Lange
Has grant
Scientist II
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Treating Hearts at Risk for Cardiomyopathy: Leveraging Human iPSC Disease Models
Open Date: 2025-06-01
Close Date: 2026-05-01
Grant: Close
Developing Novel Atrial-like Engineered Cardiac Tissue for Modeling Cardiac Pressure Overload and Atrial Fibrillation
Open Date: 2022-07-01
Close Date: 2023-06-01
Grant: Close
Mechanism of regulation of cardiac contraction by phosphorylation of myosin binding protein C
Open Date: 2018-07-01
Close Date: 2023-06-30
Grant: Close
Top-Down Proteomics of Myofilaments in Heart Failure
Open Date: 2011-08-05
Close Date: 2022-11-30
Grant: Close
Murine 3D Engineered Tissue Model of Human MYBPC3 Mutations
Open Date: 2011-06-13
Close Date: 2017-05-31
Articles (7)
Year:
2026
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Truncation mutations in cardiac myosin binding protein C (cMyBP-C) are common causes of hypertrophic cardiomyopathy (HCM). Heterozygous carriers present with classical HCM, while homozygous carriers present with early onset HCM that rapidly progress to heart failure. We used CRISPR-Cas9 to introduce heterozygous (cMyBP-C+/−) and homozygous (cMyBP-C−/−) frame-shift mutations into MYBPC3 in human iPSCs. Cardiomyocytes derived from these isogenic lines were used to generate cardiac micropatterns and engineered cardiac tissue constructs (ECTs) that were characterized for contractile function, Ca2+-handling, and Ca2+-sensitivity. While heterozygous frame shifts did not alter cMyBP-C protein levels in 2-D cardiomyocytes, cMyBP-C+/− ECTs were haploinsufficient. cMyBP-C−/− cardiac micropatterns produced increased strain with normal Ca2+-handling. After 2 wk of culture in ECT, contractile function was similar between the three genotypes; however, Ca2+-release was slower in the setting of reduced or absent cMyBP-C. At 6 wk in ECT culture, the Ca2+-handling abnormalities became more pronounced in both cMyBP-C+/− and cMyBP-C−/− ECTs, and force production became severely depressed in cMyBP-C−/− ECTs. RNA-seq analysis revealed enrichment of differentially expressed hypertrophic, sarcomeric, Ca2+-handling, and metabolic genes in cMyBP-C+/− and cMyBP-C−/− ECTs. Our data suggest a progressive phenotype caused by cMyBP-C haploinsufficiency and ablation that initially is hypercontractile, but progresses to hypocontractility with impaired relaxation. The severity of the phenotype correlates with the amount of cMyBP-C present, with more severe earlier phenotypes observed in cMyBP-C−/− than cMyBP-C+/− ECTs. We propose that while the primary effect of cMyBP-C haploinsufficiency or ablation may relate to myosin crossbridge orientation, the observed contractile phenotype is Ca2+-mediated.
Year:
2023
Year:
2023
Collaborators (8)
Alexey Glukhov
Associate Professor
Imperial College London
Morgan Mann
Assistant Professor (CHS)
University of Wisconsin-Madison
J. Carter Ralphe
University of Wisconsin-Madison
Christopher Coe
Professor
University of Wisconsin-Madison
Eric Schmuck
Research Assistant Professor
University of Wisconsin-Madison
Timothy Kamp
Professor
University of Wisconsin-Madison
Di Lang
Assistant Professor
University of California, San Francisco
Angela Greenman
University of Wisconsin-Madison
Make your next move.
Prepare your application
Review drafts before you send them.